- Home
- CARV vs CMMB Comparison
CARV vs CMMB Comparison
Compare CARV & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARV
- CMMB
- Stock Information
- Founded
- CARV 1948
- CMMB 2004
- Country
- CARV United States
- CMMB Israel
- Employees
- CARV N/A
- CMMB N/A
- Industry
- CARV Savings Institutions
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- CARV Finance
- CMMB Health Care
- Exchange
- CARV Nasdaq
- CMMB Nasdaq
- Market Cap
- CARV 14.5M
- CMMB 13.8M
- IPO Year
- CARV 1994
- CMMB N/A
- Fundamental
- Price
- CARV $1.59
- CMMB $2.54
- Analyst Decision
- CARV
- CMMB Strong Buy
- Analyst Count
- CARV 0
- CMMB 2
- Target Price
- CARV N/A
- CMMB $26.50
- AVG Volume (30 Days)
- CARV 62.7K
- CMMB 80.5K
- Earning Date
- CARV 11-13-2025
- CMMB 11-20-2025
- Dividend Yield
- CARV N/A
- CMMB N/A
- EPS Growth
- CARV N/A
- CMMB N/A
- EPS
- CARV N/A
- CMMB N/A
- Revenue
- CARV $22,310,000.00
- CMMB N/A
- Revenue This Year
- CARV N/A
- CMMB N/A
- Revenue Next Year
- CARV N/A
- CMMB N/A
- P/E Ratio
- CARV N/A
- CMMB N/A
- Revenue Growth
- CARV N/A
- CMMB N/A
- 52 Week Low
- CARV $1.30
- CMMB $2.36
- 52 Week High
- CARV $3.85
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- CARV 26.80
- CMMB 42.45
- Support Level
- CARV $1.41
- CMMB $2.36
- Resistance Level
- CARV $1.68
- CMMB $2.85
- Average True Range (ATR)
- CARV 0.26
- CMMB 0.20
- MACD
- CARV -0.22
- CMMB -0.02
- Stochastic Oscillator
- CARV 10.26
- CMMB 32.71
About CARV Carver Bancorp Inc.
Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.